<DOC>
<DOCNO>EP-0648117</DOCNO> 
<TEXT>
<INVENTION-TITLE>
DRUGS FOR PREVENTING THE DEVELOPMENT OF TOLERANCE DURING TREATMENT WITH BENZODIAZEPINE-RECEPTOR-BINDING SUBSTANCES
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K3100	A61K3166	A61K3100	A61P2530	A61P2500	A61K3166	A61K31675	A61K31675	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61K	A61P	A61P	A61K	A61K	A61K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	A61K31	A61P25	A61P25	A61K31	A61K31	A61K31	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Described is the use of NMDA-receptor antagonists or physiologically tolerated salts thereof to prevent the development of tolerance during chronic treatment with benzodiazepine-receptor-binding substances. Also described is the combination of the new drugs with benzodiazepine-receptor-binding substances.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
SCHERING AG
</APPLICANT-NAME>
<APPLICANT-NAME>
SCHERING AKTIENGESELLSCHAFT
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
SCHNEIDER HERBERT
</INVENTOR-NAME>
<INVENTOR-NAME>
STEPHENS DAVID NORMAN
</INVENTOR-NAME>
<INVENTOR-NAME>
STEPPUHN KARIN GABRIELE
</INVENTOR-NAME>
<INVENTOR-NAME>
TURSKI LECHOSLAW
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHNEIDER, HERBERT
</INVENTOR-NAME>
<INVENTOR-NAME>
STEPHENS, DAVID, NORMAN
</INVENTOR-NAME>
<INVENTOR-NAME>
STEPPUHN, KARIN, GABRIELE
</INVENTOR-NAME>
<INVENTOR-NAME>
TURSKI, LECHOSLAW
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Use of competitive and non-competitive NMDA antagonists or the physiologically 
tolerable salts thereof for the manufacture of medicaments for the prophylaxis of the 

development of tolerance for benzodiazepine-receptor-binding active ingredients. 
Use according to claim 1, characterised in that the treatment is used together with 
benzodiazepine receptor-binding active ingredients. 
Use according to claim 1 or claim 2, characterised in that the non-competitive NMDA 
antagonist is an antagonist of the glycine-binding site. 
Use according to claim 1 or claim 2, characterised in that the NMDA antagonist is a 
competitive NMDA antagonist. 
</CLAIMS>
</TEXT>
</DOC>
